ASCO 2010 Renel Cell Carcinoma

Article

ASCO 2010 Renal Cell Carcinoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Related Content
Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.

Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population

Russ Conroy
August 19th 2025
Article
Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 19th 2025
Podcast
The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 19th 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 19th 2025
Podcast
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Roman Fabbricatore
August 19th 2025
Article
Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

ONCOLOGY Staff
August 19th 2025
Article